Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling

In the context of serum amyloid A (SAA) identification as ovarian cancer marker derived by SELDI‐MS, its serum levels were measured by immunoassay in different stages of ovarian cancer, in benign gynecological tumors, and in healthy controls. In addition, SELDI‐TOF‐MS spectra were obtained by protocol optimized for the SAA peak intensity. SELDI data on small proteins (5.5–17.5 kDa) and SAA immunoassay data were combined with cancer antigen (CA)125 data in order to study the classification accuracy between cancer and noncancer by support vector machine (SVM), logistic regression, and top scoring pair classifiers. Although an addition of SAA immunoassay data to CA125 data did not significantly improve cancer/noncancer discrimination, SVM applied to combined biomarker data (CA125 and SAA immunoassay variables plus 48 SELDI peak variables) yielded the best classification rate (accuracy 95.2% vs. 86.2% for CA125 alone). Notably, most of discriminatory peaks selected by the classifiers have significant correlation with the major known peaks of SAA (11.7 kDa) and transthyretin (13.9 kDa). Acute phase serum amyloid A (A‐SAA) was proved to be an important member of cancer discriminatory protein profile. Among the eight known ovarian cancer SELDI profile components, A‐SAA is the most relevant to molecular pathogenesis of cancer and it has the highest degree of up‐regulation in disease.

[1]  Andrew J. Lindsay,et al.  Acute phase proteins in salmonids: evolutionary analyses and acute phase response. , 1997, Journal of immunology.

[2]  Vladimir Vapnik,et al.  Statistical learning theory , 1998 .

[3]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[4]  J. García-Arrarás,et al.  Serum amyloid A protein in an echinoderm: its primary structure and expression during intestinal regeneration in the sea cucumber Holothuria glaberrima. , 2000, The Journal of experimental zoology.

[5]  Alexander S Whitehead,et al.  Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue , 2000, Arthritis research.

[6]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[7]  G. Yousef,et al.  Human Tissue Kallikreins: A New Enzymatic Cascade Pathway? , 2002, Biological chemistry.

[8]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[9]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[10]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Glimm,et al.  Detection of cancer-specific markers amid massive mass spectral data , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Michael J Campa,et al.  Identification and validation of a potential lung cancer serum biomarker detected by matrix‐assisted laser desorption/ionization‐time of flight spectra analysis , 2003, Proteomics.

[13]  David Ward,et al.  Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data , 2003, Bioinform..

[14]  R. Nelson,et al.  Detection of novel truncated forms of human serum amyloid A protein in human plasma , 2003, FEBS letters.

[15]  A. Vlahou,et al.  Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data , 2003, Journal of biomedicine & biotechnology.

[16]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[17]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[18]  Usha Menon,et al.  Progress and Challenges in Screening for Early Detection of Ovarian Cancer* , 2004, Molecular & Cellular Proteomics.

[19]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[20]  Steven J Skates,et al.  Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Bresnihan,et al.  Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. , 2004, Arthritis and rheumatism.

[22]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[23]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[24]  M. Hersberger,et al.  High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease , 2004, Current opinion in lipidology.

[25]  E. Birney,et al.  The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.

[26]  Jason Weston,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2002, Machine Learning.

[27]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[28]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[29]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[30]  Gilbert S Omenn,et al.  Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: Systematic variation between sample types and calibration of mass spectrometry data , 2005, Proteomics.

[31]  K. Miyazaki,et al.  Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma , 2005, British Journal of Cancer.

[32]  M. Zugaib,et al.  Maternal and Cord Blood Levels of Serum Amyloid A, C-Reactive Protein, Tumor Necrosis Factor-α, Interleukin-1β, and Interleukin-8 During and After Delivery , 2005, Mediators of inflammation.

[33]  Daniel Q. Naiman,et al.  Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data , 2005, Bioinform..

[34]  Florian J Schweigert,et al.  Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients , 2005, BMC Cancer.

[35]  Habtom W. Ressom,et al.  Analysis of mass spectral serum profiles for biomarker selection , 2005, Bioinform..

[36]  Xiao-Ying Meng,et al.  Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.

[37]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[38]  Z. Ackerman,et al.  Expression of Serum Amyloid A, in Normal, Dysplastic, and Neoplastic Human Colonic Mucosa: Implication for a Role in Colonic Tumorigenesis , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.